Cited by 687HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Open access

Wheeler, Deric L., Dunn, Emily F., Harari, Paul M.·2010·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2010.97PMC PMC2929287

Open this paper in CoChat — free account

Abstract

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis. EGFR has been strongly implicated in the biology of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas. Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising molecular inhibitors for use in clinical oncology. As is common in cancer therapy, challenges with respect to treatment resistance emerge over time. This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized. In this Review, we provide a brief overview regarding the biology of EGFR, preclinical and clinical development of EGFR inhibitors, and molecular mechanisms that underlie the development of treatment resistance. A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2010.97

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877

Flagged first, then by citations

Show all 182 references

Sorted by citations

Items 101–200 of 687

ADAM17: An Emerging Therapeutic Target for Lung Cancer
Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 81
Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer
Beyer, I., van Rensburg, R., Strauss, R., Li, Z., Wang, H., Persson, J., Yumul, R., Feng, Q., Song, H., Bártek, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2009 · Cited by 79
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Braig, F., Voigtlaender, M., Schieferdecker, A., Busch, C., Laban, S. A., Grob, T. J., Kriegs, M., Knecht, R., Bokemeyer, C., & Binder, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8943 · Cited by 82
The potential of multi-compound nanoparticles to bypass drug resistance in cancer
Silva, C. G. D., Peters, G. J., OSSENDORP, F. A., & Cruz, L. J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3427-1 · Cited by 80
EGFR Modulates DNA Synthesis and Repair through Tyr Phosphorylation of Histone H4
Chou, R., Wang, Y., Hsieh, Y., Li, L., Xia, W., Chang, W., Chang, L., Cheng, C.-C., Lai, C., Hsu, J. L., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.008 · Cited by 78
The Emerging Role of Adhesion GPCRs in Cancer
Gad, A. A., & Balenga, N. A. B. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00093 · Cited by 74
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance
Hegedüs, C., Truta-Feles, K., Antalffy, G., Várady, G., Német, K., Özvegy‐Laczka, C., Kéri, G., Őrfi, L., Szakács, G., Settleman, J. E., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.04.010 · Cited by 76
Inhibition of the PI 3K/ AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple‐negative breast cancer cells
Yi, Y. W., Hong, W., Kang, H. J., Kim, H. J., Zhao, W., Wang, A., Seong, Y., & Bae, I. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12046 · Cited by 76
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
Iida, M., Brand, T. M., Starr, M. M., Li, C., Huppert, E. J., Luthar, N., Pedersen, M. W., Horak, I. D., Kragh, M., & Wheeler, D. L. (2013) · Neoplasia · doi:10.1593/neo.131584 · Cited by 75
Self-citation
Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway
D’Ambrosio, S. M., Han, C., Li, P., Kinghorn, A. D., & Ding, H. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.05.027 · Cited by 75
Blood-based tumor biomarkers in lung cancer for detection and treatment
Mamdani, H. M., Ahmed, S. S., Armstrong, S. A., Mok, T. S. K., & Jalal, S. I. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.03 · Cited by 75
The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha
Bou-Dargham, M. J., Khamis, Z. I., Cognetta, A. B., & Sang, Q. A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21406 · Cited by 76
Viruses exploit the function of epidermal growth factor receptor
Zheng, K., Kitazato, K., & Wang, Y. (2014) · Reviews in Medical Virology · doi:10.1002/rmv.1796 · Cited by 76
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
Adams, S., Yang, H. C., Savariar, E. N., Aguilera, J. A., Crisp, J. L., Jones, K. A., Whitney, M. A., Lippman, S. M., Cohen, E. E. W., Tsien, R. Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13019 · Cited by 72
Tumor Metabolism of Malignant Gliomas
Ru, P., Williams, T. M., Chakravarti, A., & Guo, D. (2013) · Cancers · doi:10.3390/cancers5041469 · Cited by 73
Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer
Lin, F., Wen, D., Wang, X., & Mahato, R. I. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.036 · Cited by 72
EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy
Zahonero, C., & Sánchez‐Gómez, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1608-1 · Cited by 71
Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
Tang, J., Salama, R., Gadgeel, S. M., Sarkar, F. H., & Ahmad, A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00015 · Cited by 73
Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
Dokala, A., & Thakur, S. S. (2016) · Oncogene · doi:10.1038/onc.2016.393 · Cited by 70
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
Hingorani, D. V., Allevato, M. M., Camargo, M. F., Lesperance, J., Quraishi, M. A., Aguilera, J. A., Pietryga, I. F., Scanderbeg, D. J., Wang, Z., Molinolo, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31601-z · Cited by 73
Autonomous bacterial localization and gene expression based on nearby cell receptor density
Wu, H., Tsao, C., Quan, D. N., Cheng, Y., Servinsky, M. D., Carter, K. K., Jee, K. J., Terrell, J. L., Zargar, A., Rubloff, G. W., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.71 · Cited by 69
Targeting Myristoylated Alanine-Rich C Kinase Substrate Phosphorylation Site Domain in Lung Cancer. Mechanisms and Therapeutic Implications
Chen, C., Statt, S. N., Chiu, C.-L., Thai, P., Arif, M., Adler, K. B., & Wu, R. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1505oc · Cited by 70
Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides
Yu, Y., Chou, R., Liang, J.-H., Chang, W.-J., Su, K., Tseng, Y.-J., Huang, W., Wang, S., & Hung, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061362 · Cited by 69
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T. J., Alawi, M., Indenbirken, D., Kriegs, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3574 · Cited by 67
Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
Li, X., Cai, W., Yang, G., Su, C., Ren, S., Zhao, C., Hu, R., Chen, X., Gao, G., Guo, Z., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.006 · Cited by 67
The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network
Iwamoto, M., Saso, W., Nishioka, K., Ohashi, H., Sugiyama, R., Ryo, A., Ohki, M., Yun, J.-H., Park, S., Ohshima, T., et al. (2020) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)49936-4 · Cited by 67
Next-generation sequencing and epigenome technologies: potential medical applications
Roukos, D. H. (2010) · Expert Review of Medical Devices · doi:10.1586/erd.10.68 · Cited by 67
STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3
Han, W., Carpenter, R. L., Cao, X., & Lo, H. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21936 · Cited by 68
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck
Stegeman, H., Kaanders, J. H. A. M., Wheeler, D. L., van der Kogel, A. J., Verheijen, M. M., Waaijer, S. J. H., Iida, M., Grenman, R. A., Span, P. N., & Bussink, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-463 · Cited by 66
Self-citation
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis
Lu, H., Li, X.-Q., Lu, Y., Qiu, S., & Fan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.020 · Cited by 58
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Iida, M., Brand, T. M., Starr, M. M., Huppert, E. J., Luthar, N., Bahrar, H., Coan, J. P., Pearson, H. E., Salgia, R., & Wheeler, D. L. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-242 · Cited by 63
Self-citation
Oncogenic miR-9 is a target of erlotinib in NSCLCs
Chen, X., Zhu, L., Ma, Z., Sun, G., Luo, X., Li, M., Zhai, S., Li, P., & Wang, X. (2015) · Scientific Reports · doi:10.1038/srep17031 · Cited by 63
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Okada, Y., Kimura, T., Nakagawa, T., Okamoto, K., Fukuya, A., Goji, T., Fujimoto, S., Sogabe, M., Miyamoto, H., Muguruma, N., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0383 · Cited by 63
Lycorine inhibits glioblastoma multiforme growth through EGFR suppression
Shen, J., Zhang, T., Cheng, Z., Zhu, N., Wang, H., Li, L., Wang, Z., Yi, H., & Hu, M. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0785-4 · Cited by 63
Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
Santoro, V., Jia, R., Thompson, H., Nijhuis, A. M., Jeffery, R. E., Kiakos, K., Silver, A. R., Hartley, J. A., & Hochhauser, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv394 · Cited by 61
β1, 4-N-acetylgalactosaminyltransferase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells
Che, M., Huang, J. C., Hung, J., Lin, Y.-C., Huang, M.-J., Lai, H., Hsu, W., Liang, J., & Huang, M. (2014) · Oncotarget · doi:10.18632/oncotarget.1981 · Cited by 62
Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition
Choe, C., Shin, Y.-S., Choi, S., Lee, J., Kim, S. Y., Cho, Y. B., Kim, J., & Kim, C. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89659 · Cited by 64
Mechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 65
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
Lou, W., Chen, Y., Zhu, K., Deng, H., Wu, T., & Wang, J. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00271 · Cited by 62
Quercetin preferentially induces apoptosis in KRAS‐mutant colorectal cancer cells via JNK signaling pathways
Yang, Y., Wang, T., Chen, D., Ma, Q., Zheng, Y., Liao, S., Wang, Y., & Zhang, J. (2018) · Cell Biology International · doi:10.1002/cbin.11055 · Cited by 61
ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
Wang, Y., Godin-Heymann, N., WANG, X.-D., Bergamaschi, D., Llanos, S., & Lü, X. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.3 · Cited by 60
Site-specific activation of AKT protects cells from death induced by glucose deprivation
Gao, M., Liang, J., Lu, Y., Guo, H., German, P., Bai, S., Jonasch, E., Yang, X., Mills, G. B., & Ding, Z. (2013) · Oncogene · doi:10.1038/onc.2013.2 · Cited by 60
Novel application of metformin combined with targeted drugs on anticancer treatment
Deng, J., Peng, M., Wang, Z., Zhou, S., Xiao, D., Deng, J., Yang, X., Peng, J.-Y., & Yang, X. (2018) · Cancer Science · doi:10.1111/cas.13849 · Cited by 59
Gefitinib
Rahman, A. F. M. M., Korashy, H. M., & Kassem, M. G. (2014) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/b978-0-12-800173-8.00005-2 · Cited by 58
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
Kim, M. H., Kim, H. R., Cho, B. C., Bae, M. K., Kim, E. Y., Lee, C. Y., Lee, J. S., Kang, D. R., & Kim, J. H. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.022 · Cited by 57
2-Aminobenzothiazoles in anticancer drug design and discovery
Huang, G., Cierpicki, T., & Grembecka, J. E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106477 · Cited by 60
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody89Zr-RG7116
van Scheltinga, A. G. T. T., Hooge, M. N. L., Abiraj, K., Schröder, C. P., Pot, L., Bossenmaier, B., Thomas, M., Hölzlwimmer, G., Friess, T., Kosterink, J. G. W., et al. (2014) · mAbs · doi:10.4161/mabs.29097 · Cited by 55
Combination of Gefitinib and DNA Methylation Inhibitor Decitabine Exerts Synergistic Anti-Cancer Activity in Colon Cancer Cells
Lou, Y.-F., Zou, Z., Chen, P., Huang, G., Li, B., Zheng, D.-Q., Yu, X., & Luo, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097719 · Cited by 55
The Cell Surface Glycoprotein CUB Domain-containing Protein 1 (CDCP1) Contributes to Epidermal Growth Factor Receptor-mediated Cell Migration
Dong, Y., He, Y., de Boer, L., Stack, M. S., Lumley, J. W., Clements, J. A., & Hooper, J. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.335448 · Cited by 55
Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer
Elbaz, M., Ahirwar, D. K., Ravi, J., Nasser, M. W., & Ganju, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.9408 · Cited by 55
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Ortiz‐Cuaran, S., Bouaoud, J., Karabajakian, A., Fayette, J., & Saintigny, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614332 · Cited by 59
YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
Na, Y.-S., Yang, S., Kim, S.-M., Jung, K.-A., Moon, J.-H., Shin, J.-S., Yoon, D. H., Hong, Y. S., Ryu, M., Lee, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038625 · Cited by 54
Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
Sebastian, A., Pandey, V., Mohan, C. D., Chia, Y. T., Rangappa, S., Mathai, J., Baburajeev, C. P., Paricharak, S., Mervin, L., Bulusu, K. C., et al. (2016) · ACS Omega · doi:10.1021/acsomega.6b00251 · Cited by 54
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
Wu, Y.-Y., Wu, H., Wu, J.-E., Huang, K., Yang, S., Chen, S.-X., Tsao, C.-J., Hsu, K., Chen, Y., & Hong, T.-M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1282-0 · Cited by 59
The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network
Iwamoto, M., Saso, W., Nishioka, K., Ohashi, H., Sugiyama, R., Ryo, A., Ohki, M., Yun, J.-H., Park, S., Ohshima, T., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.010366 · Cited by 54
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib
Ли, Б., Shin, H., Gulbekyan, G., Pustovalova, O., Nikolsky, Y., Hope, A. J., Bessarabova, M., Schu, M. C., Kolpakova-Hart, E., Merberg, D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130700 · Cited by 53
Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer
Lee, C., Syu, S., Liu, K., Chu, P., Yang, W., Lin, P., & Shieh, W.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5640 · Cited by 53
177Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model
Liu, Z., Ma, T., Liu, H., Jin, Z., Sun, X., Zhao, H., Shi, J., Jia, B., Li, F., & Wang, F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4005047 · Cited by 53
The Landscape of EGFR Pathways and Personalized Management of Non-Small-Cell Lung Cancer
Liang Cheng, C., Zhang, S., Alexander, R. E., Yao, Y., MacLennan, G. T., Pan, C.-X., Huang, J., Wang, M., Montironi, R., & Antonio Lopez-beltran, B. (2011) · Future Oncology · doi:10.2217/fon.11.25 · Cited by 53
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
Ding, C., Chen, S., Zhang, C., Hu, G., Zhang, W., Li, L., Chen, Y., Tan, C., & Jiang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.006 · Cited by 53
Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling
Kim, Y., Jung, K., Beak, D., Hong, S.-S., & Kim, Y. (2016) · Oncogene · doi:10.1038/onc.2016.407 · Cited by 53
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 55
A Fourteen Gene GBM Prognostic Signature Identifies Association of Immune Response Pathway and Mesenchymal Subtype with High Risk Group
Arivazhagan, A., Somasundaram, K., Thennarasu, K., Sreekanthreddy, P., Srinivasan, H., Shailaja, B. C., Samuel, C., Patric, I. R. P., Shukla, S. K., Thota, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062042 · Cited by 52
Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
Li, J., Yan, H., Zhao, L., Jia, W., Yang, H., Liu, L., Zhou, X., Miao, P., Sun, X., Song, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10721 · Cited by 52
Inhibition of histone deacetylases sensitizes EGF receptor‐TK inhibitor‐resistant non‐small‐cell lung cancer cells to erlotinib in vitro and in vivo
Yu, W., Lü, W., Chen, G., Cheng, F., Su, H., Chen, Y., Liu, M., & Pang, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13961 · Cited by 52
PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα
Dopeso, H., Jiao, H., Cuesta, Á. M., Henze, A., Jurida, L., Kracht, M., Acker‐Palmer, A., Garvalov, B. K., & Acker, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1346 · Cited by 52
Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress
Wang, C. Y., Guo, S., Wang, J. Y., Liu, F., Zhang, Y. Y., Yari, H., Yan, X. G., Jin, L., Zhang, X. D., & Jiang, C. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0778 · Cited by 52
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.
Gomez, G. G., Wykosky, J., Zanca, C., Furnari, F. B., & Cavenee, W. K. (2013) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2013.04.003 · Cited by 53
High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer
Jeantet, M., Tougeron, D., Tachon, G., Cortes, U., Archambaut, C., Fromont, G., & Karayan, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122015 · Cited by 51
MicroRNAs in cancer therapeutic response: Friend and foe
Xue, J. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.730 · Cited by 50
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
Novel Therapy Based on Camelid Nanobodies
Unciti-Broceta, J. D., del Castillo-Santaella, T., Soriano, M., Magez, S., & Garcia-Salcedo, J. A. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.87 · Cited by 51
ERBB oncogene proteins as targets for monoclonal antibodies
Polanovsky, O. L., Lebedenko, E. N., & Deyev, S. M. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912030029 · Cited by 49
Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines
Piscazzi, A., Costantino, E., Maddalena, F., Natalicchio, M. I., Gerardi, A. M. T., Antonetti, R., Cignarelli, M., & Landriscina, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3269 · Cited by 49
Thioaryl Naphthylmethanone Oxime Ether Analogs as Novel Anticancer Agents
Chakravarti, B., Akhtar, T., Rai, B., Yadav, M. K., Siddiqui, J. A., Dwivedi, S. K. D., Thakur, R. K., Singh, A. K., Singh, A. K., Kumar, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500873e · Cited by 49
Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells
Saki, M. R., Toulany, M., & Rodemann, H. P. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.023 · Cited by 48
Emerging drugs for head and neck cancer
Wen, Y., & Grandis, J. R. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1031653 · Cited by 48
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab
Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24342 · Cited by 48
Self-citation
Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation
Huang, Y., Benaich, N., Tape, C. J., Kwok, H. F., & Murphy, G. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9326 · Cited by 48
mTOR inhibitors radiosensitize PTEN‐deficient non‐small‐cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
Kim, E. J., Jeong, J., Bae, S., Kang, S., Kim, C. H., & Lim, Y. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24465 · Cited by 48
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
Fleuren, E. D. G., Versleijen‐Jonkers, Y. M. H., Boerman, O. C., & van der Graaf, W. T. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.005 · Cited by 47
Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells
Oliveras‐Ferraros, C., Vazquez‐Martin, A., Cufí, S., Queralt, B., Báez, L., Guardeño, R., Hernández‐Yagüe, X., Martin‐Castillo, B., Brunet, J., & Menendez, J. A. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22952 · Cited by 47
Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2
van Dijk, L. K., Hoeben, B. A. W., Kaanders, J. H. A. M., Franssen, G. M., Boerman, O. C., & Bussink, J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.123612 · Cited by 47
Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo
Qayum, N., Im, J. H., Stratford, M. R. L., Bernhard, E. J., McKenna, W. G., & Muschel, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1413 · Cited by 47
Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A
Wang, W., Zhang, H., Liu, S., Kim, C. K., Xu, Y., Hurley, L., Nishikawa, R., Nagane, M., Hu, B., Stegh, A. H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701289114 · Cited by 48
The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
Owczarek, W. D., Słowińska, M., Lesiak, A., Ciążyńska, M. A., Maciąg, A., Paluchowska, E. B., Marek‐Józefowicz, L., & Czajkowski, R. (2017) · Advances in Dermatology and Allergology · doi:10.5114/ada.2017.71106 · Cited by 46
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer
Lin, L., Fei, X., Chen, L., Yao, L., & Lei, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1381251 · Cited by 52
Quantification and Kinetic Analysis of Grb2-EGFR Interaction on Micro-Patterned Surfaces for the Characterization of EGFR-Modulating Substances
Lanzerstorfer, P., Borgmann, D. M., Schütz, G. J., Winkler, S., Höglinger, O., & Weghuber, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092151 · Cited by 46
EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src
Begley, M. J., Yun, C., Gewinner, C. A., Asara, J. M., Johnson, J. L., Coyle, A. J., Eck, M. J., Apostolou, I., & Cantley, L. C. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3117 · Cited by 46
Activation of Epidermal Growth Factor Receptor in Macrophages Mediates Feedback Inhibition of M2 Polarization and Gastrointestinal Tumor Cell Growth
Zhao, G., Liu, L., Peek, R. M., Hao, X., Polk, D. B., Li, H., & Yan, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.750182 · Cited by 46
Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses
Wu, Y., Wen, H., Bernstein, Z. J., Hainline, K. M., Blakney, T. S., Congdon, K. L., Snyder, D. J., Sampson, J. H., Sanchez-Perez, L. A., & Collier, J. H. (2022) · Science Advances · doi:10.1126/sciadv.abm7833 · Cited by 48
Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation
Tripathi, K. K., Hussein, U. K., Anupalli, R. R., Barnett, R. M., Bachaboina, L., Scalici, J. M., Rocconi, R. P., Owen, L. B., Piazza, G. A., & Palle, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3026 · Cited by 45
Cetuximab alleviates neuropathic pain despite tumour progression
Kersten, C., & Cameron, M. G. (2012) · BMJ Case Reports · doi:10.1136/bcr.12.2011.5374 · Cited by 45
Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles
Petrilli, R., Pinheiro, D. P., de Oliveira, F. D. C. E., Galvão, G. F., Marques, L. G. A., Lopez, R. F. V., Pessoa, C., & Eloy, J. O. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200525161359 · Cited by 45
Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis
Berger, C., Madshus, I. H., & Stang, E. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.09.001 · Cited by 44
Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas
Smilek, P., Neuwirthová, J., Jarkovský, J., Dušek, L., Rottenberg, J., Kostřica, R., Srovnal, J., Hajdúch, M., Drábek, J., & Klozar, J. (2012) · Neoplasma · doi:10.4149/neo_2012_065 · Cited by 45
EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK
Mueller, K. L., Powell, K., Madden, J. M., Eblen, S. T., & Boerner, J. L. (2012) · Translational Oncology · doi:10.1593/tlo.12163 · Cited by 44
Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis
Bello, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.042 · Cited by 42
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
Young, N. R., Liu, J., Pierce, C., Wei, T.-F., Grushko, T. A., Olopade, O. I., Liu, W., Shen, C. P., Seiwert, T. Y., & Cohen, E. E. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.11.001 · Cited by 43

Authors: Wheeler, D. L., Dunn, E. F., & Harari, P. M.
Affiliations: University of Wisconsin–Madison (US)
Corresponding author: Wheeler, Deric L.
ORCID: Wheeler, Deric L.
Dunn, Emily F.
Harari, Paul M.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2010-06-15
Volume: 7
Issue: 9
Pages: 493-507
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2010.97
PMC: PMC2929287
OpenAlex: W2053439872
Cited by: 683
References: 182
Citations by year: 2026: 21 · 2025: 20 · 2024: 35 · 2023: 29 · 2022: 31 · 2021: 29 · 2020: 44 · 2019: 25 · 2018: 36 · 2017: 50 · 2016: 46 · 2015: 61 · 2014: 66 · 2013: 68 · 2012: 64
FWCI: 6.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5t32ca009614-25)
U.S. Public Health Service (P30CAO14520)
National Cancer Institute (T-32 CA 0096-14, R01CA113448)
National Center for Research Resources (UL1RR025011)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: EGFR inhibitors, EGFR, acquired drug resistance, intrinsic resistance, tyrosine kinase inhibitors, resistance mechanisms, EGFR signaling, epithelial malignancies, lung cancer, head and neck cancer, colon cancer, pancreatic cancer, combination therapy
MeSH terms: Cetuximab, Erlotinib Hydrochloride, Gefitinib, Panitumumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Proto-Oncogene Proteins, Quinazolines, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks